OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCC

August 8th 2017

Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Dr. Black Discusses Immunotherapy Biomarkers in Bladder Cancer

August 8th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

August 8th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

Dr. Burtness on Challenges Facing Immunotherapy in Head and Neck

August 7th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Dr. Choueiri on Trials Investigating Combination Regimens for RCC

August 7th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

Dr. Leonard on Exciting Advancements in the Field of Mantle Cell Lymphoma

August 7th 2017

John P. Leonard, MD, professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

Dr. Choi on Considering Factors for RT in Prostate Cancer

August 7th 2017

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.

Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma

August 4th 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Dr. Roboz on Challenges With CAR T-cell Therapy in ALL

August 4th 2017

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Dr. Yu Compares Treatment Options for Prostate Cancer

August 4th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

Dr. Stein on Targeted Therapies for Melanoma

August 4th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at NYU Langone Medical Center, discusses targeted therapies for patients with melanoma.

Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC

August 4th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).

Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer

August 3rd 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with non-metastatic muscle invasive bladder cancer.

Dr. Choyke on Which Patients Benefit From Active Surveillance in Prostate Cancer

August 3rd 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

Dr. Furman on Second-Generation BTK Inhibitors in CLL

August 3rd 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL).

Dr. Ansell on Combining CAR T-cell Therapy and Immunotherapy in Lymphomas

August 3rd 2017

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer

August 3rd 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Dr. Weiss on the Role of Immunotherapy in Head and Neck Cancer

August 3rd 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the role of immunotherapy in head and neck cancer.

Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma

August 3rd 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

Dr. Friend on the Importance of Work-up for Patients With Multiple Myeloma

August 3rd 2017

Reed Friend, MD, a medical oncologist in hematology and medical oncology, of Levine Cancer Institute and Carolinas HealthCare System, discusses the importance of appropriate work-ups for patients with multiple myeloma.